FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226083031> ?p ?o ?g. }

• W4226083031 endingPage "e683" @default.
• W4226083031 startingPage "e683" @default.
• W4226083031 abstract "Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7-7.9), and the median number of prior treatments was 4 (interquartile range, 3-5). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1-3.8) and 7.7 months (95% CI, 5.7-9.7), respectively. For patients achieving ≥PR, median PFS and OS were 10.6 months (95% CI, 8.3-12.9) and 16.3 months (95% CI, 13.6-23.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials." @default.
• W4226083031 created "2022-05-05" @default.
• W4226083031 creator A5002972322 @default.
• W4226083031 creator A5004217461 @default.
• W4226083031 creator A5021621934 @default.
• W4226083031 creator A5040082277 @default.
• W4226083031 creator A5049413660 @default.
• W4226083031 creator A5066560929 @default.
• W4226083031 creator A5066909565 @default.
• W4226083031 creator A5068940705 @default.
• W4226083031 creator A5077074281 @default.
• W4226083031 creator A5083385949 @default.
• W4226083031 creator A5086554449 @default.
• W4226083031 creator A5087955804 @default.
• W4226083031 creator A5088671713 @default.
• W4226083031 date "2022-01-27" @default.
• W4226083031 modified "2023-09-25" @default.
• W4226083031 title "Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry" @default.
• W4226083031 cites W1703551835 @default.
• W4226083031 cites W1944400929 @default.
• W4226083031 cites W1985864219 @default.
• W4226083031 cites W1988265934 @default.
• W4226083031 cites W1988998251 @default.
• W4226083031 cites W2025837443 @default.
• W4226083031 cites W2044436186 @default.
• W4226083031 cites W2059876129 @default.
• W4226083031 cites W2091773528 @default.
• W4226083031 cites W2136541422 @default.
• W4226083031 cites W2140579395 @default.
• W4226083031 cites W2326706351 @default.
• W4226083031 cites W2335826388 @default.
• W4226083031 cites W2394652810 @default.
• W4226083031 cites W2512106959 @default.
• W4226083031 cites W2522419283 @default.
• W4226083031 cites W2890977830 @default.
• W4226083031 cites W2945852816 @default.
• W4226083031 cites W2978510275 @default.
• W4226083031 cites W2988984460 @default.
• W4226083031 cites W2996375811 @default.
• W4226083031 cites W3095134159 @default.
• W4226083031 doi "https://doi.org/10.1097/hs9.0000000000000683" @default.
• W4226083031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35106452" @default.
• W4226083031 hasPublicationYear "2022" @default.
• W4226083031 type Work @default.
• W4226083031 citedByCount "1" @default.
• W4226083031 countsByYear W42260830312023 @default.
• W4226083031 crossrefType "journal-article" @default.
• W4226083031 hasAuthorship W4226083031A5002972322 @default.
• W4226083031 hasAuthorship W4226083031A5004217461 @default.
• W4226083031 hasAuthorship W4226083031A5021621934 @default.
• W4226083031 hasAuthorship W4226083031A5040082277 @default.
• W4226083031 hasAuthorship W4226083031A5049413660 @default.
• W4226083031 hasAuthorship W4226083031A5066560929 @default.
• W4226083031 hasAuthorship W4226083031A5066909565 @default.
• W4226083031 hasAuthorship W4226083031A5068940705 @default.
• W4226083031 hasAuthorship W4226083031A5077074281 @default.
• W4226083031 hasAuthorship W4226083031A5083385949 @default.
• W4226083031 hasAuthorship W4226083031A5086554449 @default.
• W4226083031 hasAuthorship W4226083031A5087955804 @default.
• W4226083031 hasAuthorship W4226083031A5088671713 @default.
• W4226083031 hasBestOaLocation W42260830311 @default.
• W4226083031 hasConcept C119060515 @default.
• W4226083031 hasConcept C121608353 @default.
• W4226083031 hasConcept C126322002 @default.
• W4226083031 hasConcept C143998085 @default.
• W4226083031 hasConcept C2776063141 @default.
• W4226083031 hasConcept C2776364478 @default.
• W4226083031 hasConcept C2778524551 @default.
• W4226083031 hasConcept C2778527826 @default.
• W4226083031 hasConcept C2908647359 @default.
• W4226083031 hasConcept C71924100 @default.
• W4226083031 hasConcept C99454951 @default.
• W4226083031 hasConceptScore W4226083031C119060515 @default.
• W4226083031 hasConceptScore W4226083031C121608353 @default.
• W4226083031 hasConceptScore W4226083031C126322002 @default.
• W4226083031 hasConceptScore W4226083031C143998085 @default.
• W4226083031 hasConceptScore W4226083031C2776063141 @default.
• W4226083031 hasConceptScore W4226083031C2776364478 @default.
• W4226083031 hasConceptScore W4226083031C2778524551 @default.
• W4226083031 hasConceptScore W4226083031C2778527826 @default.
• W4226083031 hasConceptScore W4226083031C2908647359 @default.
• W4226083031 hasConceptScore W4226083031C71924100 @default.
• W4226083031 hasConceptScore W4226083031C99454951 @default.
• W4226083031 hasIssue "2" @default.
• W4226083031 hasLocation W42260830311 @default.
• W4226083031 hasLocation W42260830312 @default.
• W4226083031 hasLocation W42260830313 @default.
• W4226083031 hasLocation W42260830314 @default.
• W4226083031 hasLocation W42260830315 @default.
• W4226083031 hasLocation W42260830316 @default.
• W4226083031 hasLocation W42260830317 @default.
• W4226083031 hasLocation W42260830318 @default.
• W4226083031 hasOpenAccess W4226083031 @default.
• W4226083031 hasPrimaryLocation W42260830311 @default.
• W4226083031 hasRelatedWork W1522669222 @default.
• W4226083031 hasRelatedWork W1741438581 @default.
• W4226083031 hasRelatedWork W1991695056 @default.
• W4226083031 hasRelatedWork W2055453275 @default.

• next